By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site.
Industry: Biotechnology
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.
Institution %: 71.536
YTD Institution change: 2086525
InsidersInsiders %: 1.742
Insiders Purchases YTD:
Insiders Sales YTD: 157358
Insiders Net YTD: -157358
Analyst RatingsTarget Price: 88.13
Overall Rating: 3.7241
Strong Buys (5): 11
Buys (4): 4
Holds (3): 11
Sells (2): 1
Strong Sells (1): 2
52 Week Hi: 91.1
52 Week Low: 37.55
Beta: 1.674
50 Day MA: 51.2264
200 Day MA: 61.1585
Earnings / Revenue TrendsQtr Earnings Growth YOY: 0
Qtr Revenue Growth YOY: -0.993
Forward PE:
Trailing PE: